High-Flying EcoR1 Launching a Blank-Check Company

The biopharma specialist headed by one-time II Rising Star Oleg Nodelman continues to beat the major indices.

Oleg Nodelman (Amanda Gordon/Bloomberg)

Oleg Nodelman

(Amanda Gordon/Bloomberg)

One of the hottest biopharmaceutical hedge fund firms is the latest to be raising money for a new blank-check company.

EcoR1 Capital is seeking $125 million for Panacea Acquisition Corp., a special-purpose acquisition company (SPAC) looking to do some sort of deal in the biotechnology sector, according to the prospectus.


To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.